Zolunicant

Zolunicant (MM-110) is a potent inhibitor against nicotinic α3β4 receptors with an IC50 of 0.90 μM to combat addiction. Zolunicant can decrease the self-administration of several addictive agents including morphine, methamphetamine, nicotine, and ethanol in rat model. Zolunicant can be studied as a potential research for multiple forms of agent abuse[1]. Zolunicant also reveals a potent leishmanicide effect against Leishmania amazonensis[2].

Product Specifications

CAS Number

[188125-42-0]

Product Name Alternative

MM-110; (±) -18-Methoxycoronaridine

UNSPSC

12352005

Target

NAChR; Parasite

Type

Reference compound

Related Pathways

Anti-infection; Membrane Transporter/Ion Channel; Neuronal Signaling

Applications

COVID-19-immunoregulation

Field of Research

Infection; Neurological Disease

Assay Protocol

https://www.medchemexpress.com/zolunicant.html

Purity

99.29

Solubility

10 mM in DMSO

Smiles

COC([C@]12[C@@]3([H])[N@@](CCC4=C2NC5=CC=CC=C54)C[C@@](C[C@@H]3CCOC)([H])C1)=O

Molecular Formula

C22H28N2O3

Molecular Weight

368.47

References & Citations

[1]Pace CJ, et al. Novel iboga alkaloid congeners block nicotinic receptors and reduce drug self-administration. European journal of pharmacology. 2004;492 (2-3) :159-67.|[2]Delorenzi JC, et al. In vitro activities of iboga alkaloid congeners coronaridine and 18-methoxycoronaridine against Leishmania amazonensis. Antimicrob Agents Chemother. 2002;46 (7) :2111-5.|[3]Glick SD, et al. 18-Methoxycoronaridine acts in the medial habenula and/or interpeduncular nucleus to decrease morphine self-administration in rats. European journal of pharmacology. 2006;537 (1-3) :94-8.